has approved two single-pill combination medications, Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge(R) (amlodipine and valsartan), as initial or 'first-line' therapies in patients ...

Valsartan and Hydrochlorothiazide Tablets USP, 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg, had U.S. sales of approximately$1.6 billion for the 12 months ending June 30, 2012 ...

The FDA has approved Novartis’ Diovan HCT (valsartan/hydrochlorothiazide ... hypertension goals and increase compliance by reducing pill burden. These approvals were based on several clinical ...

depending on when a generic of its blockbuster blood pressure drug Diovan makes it to the market in the U.S. Diovan lost its patent in September of 2012, but the release of a copy has been delayed ...

Credit: Getty Images. The approval was based on data from 3 clinical studies that assessed the antihypertensive effect of valsartan in 290 children 1 to less than 6 years of age. The Food and Drug ...

Ranbaxy Laboratories finally received FDA approval to sell a generic version of the best-selling Diovan heart medicine. The decision means that Americans who take the high blood pressure pill ...

A common heart medication may contain a cancer-causing chemical, the FDA said. The U.S. Food and Drug Administration (FDA) is expanding a recall of a common heart medication because it may contain ...

Today it is in the driver’s seat after the agency approved its new generic Diovan to help relieve shortages ... of the ubiquitous high blood pressure drug. It said that its review of Alkem ...

BASEL -- Swiss drug-maker Novartis AG Wednesday said its best-selling drug, the high-blood-pressure treatment Diovan, was well on track to soon achieve annual sales of $4 billion. At a ...

has approved two single-pill combination medications, Diovan HCT®[*] (valsartan and hydrochlorothiazide) and Exforge® (amlodipine and valsartan), as initial or 'first-line' therapies in patients ...